Home

Heron Therapeutics, Inc. - Common Stock (HRTX)

1.3200
-0.5200 (-28.26%)
NASDAQ · Last Trade: Aug 10th, 4:30 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga.com
Via Benzinga · August 8, 2025
These stocks are moving in today's sessionchartmill.com
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · August 8, 2025
Traders are paying attention to the gapping stocks in Friday's session.chartmill.com
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · August 8, 2025
Earnings Scheduled For May 6, 2025benzinga.com
Via Benzinga · May 6, 2025
Earnings Scheduled For February 27, 2025benzinga.com
Via Benzinga · February 27, 2025
Earnings Scheduled For November 12, 2024benzinga.com
Via Benzinga · November 12, 2024
Heron Therapeutics: Q4 Earnings Insightsbenzinga.com
Via Benzinga · March 12, 2024
Preview: Heron Therapeutics's Earningsbenzinga.com
Via Benzinga · March 11, 2024
Heron (HRTX) Q2 Acute Care Jumps 56%fool.com
Via The Motley Fool · August 8, 2025
This Ryder System Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mondaybenzinga.com
Via Benzinga · June 9, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 4, 2024
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · December 4, 2024
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · November 13, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 12, 2024
HRTX Stock Earnings: Heron Therapeutics Misses EPS, Beats Revenue for Q2 2024investorplace.com
HRTX stock results show that Heron Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024
Top 3 Health Care Stocks That May Crash In Maybenzinga.com
Via Benzinga · May 24, 2024
HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024investorplace.com
HRTX stock results show that Heron Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Via Benzinga · April 23, 2024
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesdaybenzinga.com
Via Benzinga · April 23, 2024
Why Is Postoperative Pain Focused Heron Therapeutics Stock Trading Higher On Wednesday?benzinga.com
Heron Therapeutics' Q4 2023 results: Beat EPS consensus at $(0.07), $34.23 million sales, up 14% Y/Y. Strong momentum in acute and oncology care franchises. Fiscal year 2024 guidance: $138 million-$158 million revenue, with positive adjusted EBITDA.
Via Benzinga · March 13, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · March 13, 2024
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Sessionbenzinga.com
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.
Via Benzinga · March 13, 2024
Earnings Scheduled For March 12, 2024benzinga.com
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter.
Via Benzinga · March 12, 2024
Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Sessionbenzinga.com
Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.
Via Benzinga · January 24, 2024
Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nodbenzinga.com
Zynrelef's expanded FDA approval for soft tissue and orthopedic surgeries, offering superior pain management with lower pain scores and opioid consumption.
Via Benzinga · January 24, 2024